China Medical System Holdings Limited
0867
주식 순위
#4737
Established in 1995 and headquartered in North Point, Hong Kong, China Medical... Established in 1995 and headquartered in North Point, Hong Kong, China Medical System Holdings Limited functions as an investment holding company with a primary focus on the development, marketing, and distribution of a wide array of pharmaceutical products throughout the People's Republic of China. The company's extensive portfolio addresses numerous therapeutic areas. Its cardiovascular offerings include Plendil for hypertension and stable angina, XinHuoSu for acute heart failure, and Imdur for coronary heart disease, chronic heart failure, and myocardial infarction prevention. For mental health and neurological support, it provides Deanxit to treat mild-to-moderate depression and anxiety, along with Parlodel tablets for endocrine and neuro system indications. Digestive and liver conditions are managed with products such as Ursofalk for gallstones and cholestatic liver disease, Salofalk for ulcerative colitis and Crohn's disease, Bioflor for diarrhea, Combizym for dyspepsia, and Ganfule capsules for primary liver cancer, plus MOVICOL for chronic constipation. The company also markets Augentropfen Stulln Mono eye drops for senile macula degeneration and asthenopia, Hirudoid for blunt trauma and superficial phlebitis, Elcatonin injection for osteoporosis, and Lamisil tablets for fungal infections. Respiratory issues are addressed by YiNuoShu, while infectious diseases benefit from DanShenTong capsules (for various infections like acne, tonsillitis, and boils) and YinlianQinggan granules for hepatitis. XiDaKang, a protein hydrolysate oral solution, is also part of its offerings. Beyond its pharmaceutical endeavors, the group is also actively involved in agriculture and livestock operations. China Medical System Holdings Limited operates as a subsidiary of Treasure Sea Limited.
주가
$1.30
마지막 동기화: 2026-10-16
시가총액
$3.17B
변동 (1일)
-2.21%
변동 (1년)
-22.77%
국가
HK
거래 China Medical System Holdings Limited (0867)
카테고리
Healthcare
China Medical System Holdings Limited (0867)의 영업이익률
October 2026 기준 영업이익률 TTM: 19.93%
China Medical System Holdings Limited의 최신 재무 보고서와 주가에 따르면 현재 영업이익률 (TTM)은 19.93%입니다. 2023년 말 기준 영업이익률은 33.85%였습니다.
China Medical System Holdings Limited의 영업이익률 기록 (2006 ~ 2026)
매년 말 영업이익률
| 연도 | 영업이익률 | 변화 |
|---|---|---|
| 2026 (TTM) | 19.93% | -14.09% |
| 2024 | 23.20% | -31.46% |
| 2023 | 33.85% | -12.80% |
| 2022 | 38.82% | 2.73% |
| 2021 | 37.79% | -5.00% |
| 2020 | 39.78% | -8.36% |
| 2019 | 43.41% | 3.53% |
| 2018 | 41.93% | -0.33% |
| 2017 | 42.07% | 21.73% |
| 2016 | 34.56% | -1.00% |
| 2015 | 34.91% | -5.65% |
| 2014 | 37.00% | 3.70% |
| 2013 | 35.68% | -9.46% |
| 2012 | 39.41% | 20.15% |
| 2011 | 32.80% | 22.98% |
| 2010 | 26.67% | -3.23% |
| 2009 | 27.56% | 10.82% |
| 2008 | 24.87% | 24.23% |
| 2007 | 20.02% | 37.31% |
| 2006 | 14.58% | 0.00% |
유사 기업 또는 경쟁사의 영업이익률
| 회사 | 영업이익률 | 영업이익률 차이 | 국가 |
|---|---|---|---|
| 0.00% | - |
DE
|
|
| 0.00% | - |
DE
|
|
| 0.00% | - |
JP
|
|
| 0.00% | - |
CH
|
|
| 22.93% | -98.85% |
IN
|
회사의 영업이익률이란?
영업이익률은 회사의 수익성을 평가하는 핵심 지표입니다. 높은 영업이익률은 일반적으로 긍정적으로 간주되며, 이는 회사가 제품이나 서비스를 생산 비용보다 훨씬 높은 가격에 판매할 수 있음을 보여줍니다. 영업이익률은 회사의 수익을 매출로 나누어 계산합니다.